4,068 posters, 219 videos, 101 topics, 69 sessions, 14,365 authors, 6,128 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
Alzheimer's Association International Conference 2026
July 12-15, 2026 | London, United Kingdom, and Online
10812
Correlation Between Csvd Neuroimaging Biomarkers And Plasma Plgf Among Ad And Non-ad Participants In The Memory Clinic Cohort From Thailand
Poster Presenter
Authors
Thanakit Pongpitakmetha, Thanapoom Taweephol, Thachamai Smitasiri, Sekh Thanprasertsuk, Adipa Chongsuksantikul, Prawit Oangkhana, Watayuth Luechaipanit, Thanaporn Haethaisong, Jedsada Khieukhajee, Kittithatch Booncharoen, Yuttachai Likitjaroen, Poosanu Thanapornsangsuth
Affiliations
Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand, Neurological Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, 44106, USA, Department of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand, Thai Red Cross Emerging Infectious Diseases Health Science Centre, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, 10330, Thailand., Department of Neurology, Neurological Institute of Thailand, Bangkok, 10400, Thailand, Center for Medical Excellence, Faculty of Medicine, Chiangmai University, Chiangmai, 50200, Thailand, Neurocognitive Unit, Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Part of Topic
Background:
Cerebral small vessel disease (CSVD) is one of the main contributing factors to vascular cognitive impairment and dementia (VCID) in the aging population. CSVD can contribute to cognitive decline by itself or worsen cognitive decline as a co-pathology in Alzheimer’s disease (AD). Plasma placental growth factor (PlGF), a member of the vascular endothelial growth factor family, is a promising novel biomarker of subcortical white matter burden in both AD and non-AD populations. This study investigates the correlation between CSVD neuroimaging biomarkers and plasma PlGF in a memory clinic setting.
Methods:
The clinical data and plasma biomarkers were collected from memory clinic cohorts. AD and non-AD groups were defined by an abnormal cerebrospinal fluid Amyloid beta (Aβ) 42/p-tau181 ratio, or a positive Aβ Positron Emission Tomography. Magnetic resonance imaging (MRI) was independently rated by the two trained investigators using STRIVE-2 criteria (Duering M, 2023). The validated composite total CSVD score (Staals J, 2014), ranging from 0-4 was calculated. The non-parametric statistical analysis was applied to analyze.
Results:
A total of 114 participants were recruited. Clinical information, laboratory test results, and neuroimaging biomarkers were compared between AD and non-AD groups, as shown in Table 1. Plasma PlGF did not show a statistically significant difference between AD and non-AD groups. The Spearman’s correlation and the Wilcoxon rank sum test between plasma PlGF and each CSVD neuroimaging biomarker are summarized in Table 2. Plasma PlGF did not show a statistical correlation with CSVD scores or any of the CSVD neuroimaging biomarkers.
Conclusion:
Plasma PlGF showed similar values between AD and non-AD groups. Neither CSVD biomarkers nor total CSVD score correlated with plasma PlGF. These findings showed a limitation of measuring plasma PlGF as a solitary biomarker of CSVD burden in both AD and non-AD participants in a memory clinic setting. Further evaluation of the relationship between PlGF and quantitative volumetric white matter hypertensities should be explored.
Keywords: cerebral small vessel disease, placental growth factor, Alzheimer’s disease, biomarker
Comments
Email is required but is not shown publicly.
Loading comments...